What is Amgen?
Biotechnology and therapeutics company with $36.8B 2025 revenue scale and public-market buying capacity.
- Category
- Biotechnology and therapeutics
- Headquarters
- Thousand Oaks, CA
- Founded
- 1980
- Employees
- 28,000+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: AMGN; Public company
What is Amgen?
Amgen is a public biotechnology and therapeutics company headquartered in Thousand Oaks, CA. Amgen reported 2025 total revenues of $36.8 billion, up 10% from 2024.
Amgen operates in biotechnology and therapeutics with a portfolio that includes Repatha, Prolia, Enbrel, Tepezza. Amgen reported 2025 total revenues of $36.8 billion, up 10% from 2024. The company employs about 28,000+ and trades as Nasdaq: AMGN, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Amgen through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Amgen is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Amgen offer?
Amgen offers products and services across Repatha, Prolia, Enbrel, Tepezza and related healthcare workflows.
- Repatha· Cardiovascular
- Prolia· Bone health
- Enbrel· Inflammation
- Tepezza· Rare disease
- Otezla· Inflammation
- Biosimilars· Biologics
How does Amgen make money?
Amgen earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Amgen earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $36.8B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Amgen improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Amgen?
Amgen is led by Robert A. Bradway, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Robert A. BradwayChairman and Chief Executive OfficerCEO since 2012Leads Amgen's global therapeutics portfolio and capital strategy.
- Peter H. GriffithExecutive Vice President and Chief Financial OfficerCFO since 2020Oversees financial operations and investor planning.
- Paul BurtonSenior Vice President and Chief Medical OfficerCMO since 2023Guides clinical and medical strategy.
- Murdo GordonExecutive Vice President, Global Commercial OperationsCommercial leader since 2022Runs global commercial execution and market access.
How do you contact Amgen's leadership?
Amgen publishes official Amgen investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Amgen investor-relations contact route; personal executive email format not verified- Robert A. BradwayChairman and Chief Executive Officerofficial Amgen investor-relations contact route
- Peter H. GriffithExecutive Vice President and Chief Financial Officerofficial Amgen investor-relations contact route
- Paul BurtonSenior Vice President and Chief Medical Officerofficial Amgen investor-relations contact route
Sources:Amgen contactAmgen leadership
How much funding has Amgen raised?
Amgen is a mature public company, not a venture-backed startup. It trades as Nasdaq: AMGN and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Amgen's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: AMGN, $36.8B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Amgen has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Amgen get here?
Amgen grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1980Amgen foundedApplied Molecular Genetics begins in California.
- 1983IPOAmgen becomes public and scales biotechnology R&D.
- 1989Epogen approvalOne of Amgen's early breakthrough biologics reaches the market.
- 2023Horizon acquisitionAmgen expands rare disease and inflammation with Horizon Therapeutics.
- 2025$36.8B revenueAmgen reports 10% revenue growth to $36.8 billion.
- 2026Record-product momentumAmgen enters 2026 highlighting broad product growth.
Who are Amgen's competitors?
Amgen competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- RegeneronCompetes in biologics, immunology, ophthalmology-adjacent partnerships, and R&D productivity.
- NovartisCompetes in cardiovascular, immunology, oncology, and specialty biologics.
- RocheCompetes in biologics, oncology, and diagnostics-enabled medicine.
- Eli LillyCompetes in metabolic disease, immunology, oncology, and large-scale biologics.
- PfizerCompetes in inflammation, oncology, biosimilars, and hospital relationships.
- Gilead SciencesCompetes in oncology, inflammation, and specialty-biopharma budgets.
Amgen — frequently asked questions
